Patent intelligence · US
US 12251403
Genetically engineered hematopoietic stem cells and uses thereof
Genetically engineered hematopoietic stem cells and uses thereof
Patent details — US 12251403
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 18, 2025
- Expiration
- Mar 13, 2045
- Applicant
- Vor Biopharma Inc.
- Claims
- 18
- CPC classes
- A61K, A61K2035/124, A61K2039/505, A61K2239/48
Quick answer
US 12251403 (Genetically engineered hematopoietic stem cells and uses thereof) is held by Vor Biopharma Inc.. Status: granted. Granted Mar 18, 2025. Expires Mar 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vor Biopharma Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K2035/124, A61K2039/505, A61K2239/48, A61K35/28, A61K38/1774
More from Vor Biopharma Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12403200
Methods and compositions for treating autoimmune diseases
granted -
US 12291576
Anti-CD45 antibodies and conjugates thereof
granted -
US 12209135
Anti-CD45 antibodies and conjugates thereof
granted -
US 11975029
Compositions and methods for inhibition of lineage specific proteins
granted -
US 11903973
Genetically engineered hematopoietic stem cells and uses thereof
granted -
US 11571445
Genetically engineered hematopoietic stem cells and uses thereof
granted -
US 11559551
Genetically engineered hematopoietic stem cells and uses thereof
granted
Frequently asked questions
What is US patent 12251403?
US 12251403 (Genetically engineered hematopoietic stem cells and uses thereof) is held by Vor Biopharma Inc.. Status: granted. Granted Mar 18, 2025. Expires Mar 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12251403?
Vor Biopharma Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 12251403 expire?
Our index shows an expiration date of Mar 13, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.